natgillin/translations-raw huggingface dataset:
Are you taking any medicines containing: azathioprine or other immunosuppressive agents (which are sometimes given to patients after a transplant operation), cholestyramine (used to treat patients with high blood cholesterol), rifampicin (antibiotic), antacids or proton pump inhibitors (used for acid problem in your stomach such as indigestion), phosphate binders (used in patients with chronic kidney failure to reduce the absorption of phosphate) or any other medicines (including those you can buy without a prescription) that your doctor does not know about?
Kas te võtate järgmiseid aineid sisaldavaid ravimeid: asatiopriin või teised immunosupressandid (määratakse mõnikord patsientidele pärast siirdamisoperatsiooni), kolestüramiin (kasutatakse vere kõrge kolesteroolitaseme alandamiseks), rifampitsiin (antibiootikum), antatsiidid või prootonpumba inhibiitorid (kasutatakse maohappega seotud probleemide, nt seedehäire korral), fosfaate siduvad preparaadid (kasutatakse kroonilise neerupuudulikkusega patsientidel fosfaatide imendumise vähendamiseks) või teised ravimid (kaasa arvatud ilma retseptita ostetud ravimid), millest teie arst ei ole teadlik?
Are you taking any medicines containing: azathioprine or other immunosuppressive agents (which are sometimes given to patients after a transplant operation), cholestyramine (used to treat patients with high blood cholesterol), rifampicin (antibiotic), antacids or proton pump inhibitors (used for acid problem in your stomach such as indigestion), phosphate binders (used in patients with chronic kidney failure to reduce the absorption of phosphate), or any other medicines (including those you can buy without a prescription) that your doctor does not know about?
Kas te võtate järgmiseid aineid sisaldavaid ravimeid: asatiopriin või teised immunosupressandid (määratakse mõnikord patsientidele pärast siirdamisoperatsiooni), kolestüramiin (kasutatakse kõrge kolesteroolitaseme alandamiseks), rifampitsiin (antibiootikum), antatsiidid või prootonpumba inhibiitorid (kasutatakse maohappega seotud probleemide, nt seedehäire korral), fosfaate siduvad preparaadid (kasutatakse kroonilise neerupuudulikkusega patsientidel fosfaatide imendumise vähendamiseks) või teised ravimid (kaasa arvatud ilma retseptita ostetud ravimid), millest teie arst ei ole teadlik?
are  8 years of age and weigh 43.8 kg or more
on  8 aasta vanused, kehakaaluga 43,8 kg või enam
are  8 years of age and weigh 43.8 kg or more or
vähemalt 8-aastased ja kaaluvad vähemalt 43,8 kg või
are, or become dehydrated
on või tekib veetustumine (dehüdratsioon)
Area
tegevusala
AREA 1 AREA 2
PIIRKOND 1
AREA 5 AREA 6
PIIRKOND 5 PIIRKOND 6
Area in card for physician to record skin type and date of injection.
Koht kaardil, kuhu arst registreerib nahatüübi ja süsti kuupäeva.
Area under the curve (AUC0-∞)
Kõveraalune pindala (AUC0-∞)
Area under the curve: 587.88 ± 1.63 (% x h)
Kontsentratsioonikõveraalune pindala (AUC): 587,88 ± 1,63 (% x h)
Area under the plasma concentration curve (AUC) of ertapenem in adults increases nearly dose- proportionally over the 0.5 to 2 g dose range.
Ertapeneemi kontsentratsioonikõvera alune pindala (AUC) suureneb täiskasvanutel annusevahemikus 0,5...2 g peaaegu proportsionaalselt annusega.
Areas of skin without any colour (vitiligo), rash, inflamed skin (dermatitis)
Naha värvikaotus (vitiliigo), lööve, nahapõletik (dermatiit)
Areas where you may inject Rilonacept Regeneron include the left and right sides of the abdomen, and left and right thighs.
Rilonacept Regeneroni võib süstida kõhu vasakule ja paremale küljele ning vasaku ja parema reie piirkonda.
Areas with a good amount of fat below the skin (thigh, arm) are the most suitable areas to inject.
Kõige sobivamad on süstimiskohad, kus naha all on rohkem rasvkude (reis, õlavars).
Areas with scars or stretch marks should be avoided.
Vältige venitus- või muude armidega piirkondi.
Arepanrix can only be marketed when there is an official WHO/EU declaration of an influenza pandemic, on the condition that the Marketing Authorisation Holder for Arepanrix takes due account of the officially declared pandemic strain.
Arepanrix’i tohib turustada ainult juhul, kui WHO/EL on välja andnud ametliku deklaratsiooni gripi pandeemiast ning tingimusel, et Arepanrix´i müügiloa hoidja on arvesse võtnud ametlikult väljakuulutatud pandeemia tüve variatsiooni.
Arepanrix has been given ‘Conditional Approval’.
Arepanrixile anti müügiluba tingimuslikult.
Arepanrix is a vaccine to protect against ‘pandemic’ flu.
Arepanrix on vaktsiin, mida kasutatakse gripipandeemia ennetamiseks.
Arepanrix should under no circumstances be administered intravascularly.
Arepanrix’i ei tohi mitte mingil tingimusel manustada veresoonde.
Arepanrix suspension and emulsion for emulsion for injection
Arepanrix suspensioon ja emulsioon süsteemulsiooni valmistamiseks
aResponders were defined as those patients who 1) experienced a ≥ 30% drop in VASPI score compared to baseline; 2) had stable or decreased concomitant opioid analgesics; and 3) had opiate type unchanged from preinfusion if receiving opiates.
aRavile alluvatena defineeriti järgmisi patsiente: 1) kellel tekkis ≥ 30% VASPI skoori langus võrreldes algnäitajaga; 2) kes said samaaegselt stabiilses või vähenevas annuses opioidseid valuvaigisteid; ja 3) kellel opiaate kasutades ei muudetud opiaadi tüüpi eelinfusioonist alates.
aResponders were defined as those patients who 1) experienced a ≥ 30% drop in VASPI score compared to baseline; 2) had stable or decreased concomitant opioid analgesics; and 3) had opiate type unchanged from preinfusion if receiving opiates. b164 patients provided VASPI scores for ziconotide at the end of titration.
aRavile alluvatena defineeriti järgmisi patsiente: 1) kellel tekkis ≥ 30% VASPI skoori langus võrreldes algnäitajaga; 2) kes said samaaegselt stabiilses või vähenevas annuses opioidseid valuvaigisteid; ja 3) kellel opiaate kasutades ei muudetud opiaadi tüüpi eelinfusioonist alates. b164 patsiendil määrati zikonotiidi VASPI skoor tiitrimise lõppedes.
aResponders were defined as those who experienced a ≥ 30% drop in VASPI score compared to baseline.
aRavile alluvatena defineeriti patsiente, kellel tekkis ≥ 30% VASPI skoori langus võrreldes algnäitajaga.
Arginine 11
Arginiin11
Arginine hydrochloride Histidine
arginiinvesinikkloriid histidiin
Arginine, sodium acetate (E262), sodium chloride, polysorbate 80 (E433), edetate disodium (E386), hydrochloric acid (E507), water for injections.
Arginiin, naatriumatsetaat (E262), naatriumkloriid, polüsorbaat 80 (E433), edetaatdinaatrium (E386), vesinikkloriidhape (E507), süstevesi.
argininosuccinic aciduria;
argininosuktsiinatsiduuria;
ARICLAIM 30 mg hard gastro-resistant capsules
ARICLAIM 30 mg gastroresistentsed kõvakapslid
ARICLAIM 30 mg hard gastro-resistant capsules ARICLAIM 60 mg hard gastro-resistant capsules Duloxetine (as hydrochloride)
ARICLAIM 30 mg gastroresistentsed kõvakapslid ARICLAIM 60 mg gastroresistentsed kõvakapslid Duloksetiin (vesinikkloriidina)
ARICLAIM 30 mg hard gastro-resistant capsules Duloxetine
ARICLAIM 30 mg gastroresistentsed kõvakapslid Duloksetiin
ARICLAIM 30 mg hard gastro-resistant capsules.
ARICLAIM 30 mg gastroresistentsed kõvakapslid Duloksetiin
ARICLAIM 30 mg is available in packs of 7, 28 and 98 capsules.
ARICLAIM 30 mg on müügil 7, 28 ja 98 kapsliga pakenditena.
ARICLAIM 60 mg hard gastro-resistant capsules
ARICLAIM 60 mg gastroresistentsed kõvakapslid
ARICLAIM 60 mg hard gastro-resistant capsules Duloxetine
ARICLAIM 60 mg gastroresistentsed kõvakapslid Duloksetiin
ARICLAIM 60 mg hard gastro-resistant capsules.
ARICLAIM 60 mg gastroresistentsed kõvakapslid Duloksetiin
ARICLAIM 60 mg is available in packs of 28 and 98 capsules.
ARICLAIM 60 mg on müügil 28 ja 98 kapsliga pakenditena.
ARICLAIM is a hard gastro-resistant capsule.
ARICLAIM on gastroresistentne kõvakapsel.
Ariclaim may cause effects that you may not be aware of, such as increases in liver enzymes or blood levels of potassium, creatine phosphokinase, sugar, or cholesterol
ARICLAIM võib tekitada ka selliseid toimed, millest te ise teadlik ei ole, nt maksaensüümide aktiivsuse tõus või kaaliumi, kreatiinfosfokinaasi, suhkru või kolesteroolitaseme tõus veres.
ARICLAIM should not be used in the treatment of children and adolescents under the age of 18 years.
ARICLAIM-i ei tohi raviks kasutada lastel ja alla 18 aasta vanustel noorukitel.
ARIP 10-30 mg: p value 0.9920
ARIP 10...30 mg: p väärtus 0,9920
ARIP IMD 400/ 300 mg ARIP 10-30 mg
ARIP IMD 400/ 300 mg ARIP 10…30 mg
ARIP IMD 50/25 mg: p value < 0.0001
ARIP IMD 50/25 mg: p väärtus < 0,0001
Aripiprazole
Aripiprasool
Aripiprazole 10 mg (n = 27)
Aripiprasool 10 mg (n = 27)
Aripiprazole 10 mg (n = 37)
Aripiprasool 10 mg (n = 37)
Aripiprazole 10 mg (n = 44)
Aripiprasool 10 mg (n = 44)
Aripiprazole 10 mg (n = 48)
Aripiprasool 10 mg (n = 48)
Aripiprazole 10 mg (n=27)
Aripiprasool 10 mg (n = 27)
Aripiprazole 10 mg (n=37)
Aripiprasool 10 mg (n = 37)
Aripiprazole 10 mg (n=44)
Aripiprasool 10 mg (n = 44)
Aripiprazole 10 mg (n=48)
Aripiprasool 10 mg (n = 48)
Aripiprazole 30 mg (n = 25)
Aripiprasool 30 mg (n = 30)
Aripiprazole 30 mg (n = 30)
Aripiprasool 30 mg (n = 30)
Aripiprazole 30 mg (n = 48)
Aripiprasool 30 mg (n = 48)
Aripiprazole 30 mg (n = 51)
Aripiprasool 30 mg (n = 51)
Aripiprazole 30 mg (n=25)
Aripiprasool 30 mg (n = 25)
Aripiprazole 30 mg (n=30)
Aripiprasool 30 mg (n = 30)
Aripiprazole 30 mg (n=48)
Aripiprasool 30 mg (n = 48)
Aripiprazole 30 mg (n=51)
Aripiprasool 30 mg (n = 51)
Aripiprazole Accord 10 mg tablets aripiprazole
Aripiprazole Accord 10 mg tabletid aripiprasool
Aripiprazole Accord 15 mg tablets aripiprazole
Aripiprazole Accord 15 mg tabletid aripiprasool
Aripiprazole Accord 30 mg tablets are pink colored, approximately 9.1 mm in diameter, round shaped, bevelled edge, biconvex, uncoated tablets, debossed with “A30” on one side and another side is plain.
Aripiprazole Accord 30 mg tabletid on roosat värvi, ligikaudu 9,1 mm läbimõõduga, ümmargused, kaldservaga, kaksikkumerad katmata tabletid, mille ühel küljel on märgistus „A30” ja teine külg on sile.
Aripiprazole Accord 30 mg tablets aripiprazole
Aripiprazole Accord 30 mg tabletid aripiprasool
Aripiprazole Accord 5 mg tablets aripiprazole
Aripiprazole Accord 5 mg tabletid aripiprasool
Aripiprazole Accord 5 mg tablets Aripiprazole Accord 10 mg tablets Aripiprazole Accord 15 mg tablets Aripiprazole Accord 30 mg tablets
Aripiprazole Accord 5 mg tabletid Aripiprazole Accord 10 mg tabletid Aripiprazole Accord 15 mg tabletid Aripiprazole Accord 30 mg tabletid
Aripiprazole Accord 5 mg tablets Aripiprazole Accord 10 mg tablets Aripiprazole Accord 15 mg tablets Aripiprazole Accord 30 mg tablets aripiprazole
Aripiprazole Accord 5 mg tabletid Aripiprazole Accord 10 mg tabletid Aripiprazole Accord 15 mg tabletid Aripiprazole Accord 30 mg tabletid aripiprasool
Aripiprazole Accord contains lactose
Aripiprazole Accord sisaldavad laktoosi
Aripiprazole Accord contains the active substance aripiprazole and is a ‘generic medicine’.
Aripiprazole Accord sisaldab toimeainena aripiprasooli ja on geneeriline ravim.
Aripiprazole Accord is effective in a dose range of 10 to 30 mg/day.
Aripiprasool on efektiivne annuste vahemikus 10...30 mg/ööpäevas.
Aripiprazole Accord is not recommended for use in patients with schizophrenia below 15 years of age due to insufficient data on safety and efficacy (see sections 4.8 and 5.1).
Aripiprazole Accord’i ei soovitata kasutada alla 15 aasta vanuste skisofreeniaga patsientidel ohutuse ja efektiivsuse ebapiisavate andmete tõttu (vt lõigud 4.8 ja 5.1).
Aripiprazole and other antipsychotic active substances should be used cautiously in patients at risk for aspiration pneumonia.
Aripiprasooli ja teisi antipsühhootikume tuleb kasutada ettevaatusega aspiratsioonipneumoonia riskiga patsientidel.
Aripiprazole can have minor or moderate influence on the ability to drive and use machines due to potential nervous system and visual effects, such as sedation, somnolence, syncope, vision blurred, diplopia (see section 4.8).
Aripiprasool võib mõjutada kergelt või mõõdukalt autojuhtimise ja masinate käsitsemise võimet võimalike närvisüsteemi ja nägemishäirete tõttu, nagu sedatsioon, unisus, minestus, ähmane nägemine, diploopia (vt lõik 4.8).
Aripiprazole dose should be reduced to approximately one-half of its prescribed dose when concomitant administration of aripiprazole with quinidine occurs.
Kui aripiprasooli manustatakse koos kinidiiniga, tuleb aripiprasooli annus vähendada ligikaudu pooleni määratud annusest.
Aripiprazole dose should be reduced to approximately one-half of its prescribed dose when concomitant administration of aripiprazole with quinidine occurs.
Kui aripiprasooli manustatakse koos kinidiiniga, tuleb aripiprasooli annust vähendada ligikaudu pooleni määratud annusest.
Aripiprazole dose should be reduced to approximately one-half of its prescribed dose when concomitant administration of aripiprazole with quinidine occurs.
Kui aripiprasooli manustatakse koos kinidiiniga, tuleb aripiprasooli annust vähendada umbes pooleni määratud annusest.
Aripiprazole exhibited high binding affinity in vitro for dopamine D2 and D3, serotonin 5HT1a and 5HT2a receptors and moderate affinity for dopamine D4, serotonin 5HT2c and 5HT7, alpha-1 adrenergic and histamine H1 receptors.
Aripiprasool näitab kõrget sidumisafiinsust in vitro dopamiini D2 ja D3, serotoniini 5HT1a ja 5HT2a retseptoritega ja mõõdukat afiinsust dopamiini D4, serotoniini 5HT2c ning 5HT7, alfa-1-adrenergiliste ja histamiini H1 retseptoritega.
Aripiprazole exhibited high binding affinity in vitro for dopamine D2 and D3, serotonin 5HT1a and 5HT2a receptors and moderate affinity for dopamine D4, serotonin 5HT2c and 5HT7, alpha-1 adrenergic and histamine H1 receptors.
Aripiprasool näitab kõrget sidumisafiinsust in vitro dopamiini D2 ja D3, serotoniini 5HT1a ja 5HT2a retseptoritega ja mõõdukat afiinsust dopamiini D4, serotoniini 5HT2c ning 5HT7, alfaadrenergiliste ja histamiini H1 retseptoritega.
Aripiprazole is effective in a dose range of 10 to 30 mg/day.
Aripirasool on efektiivne annuste vahemikus 10 kuni 30 mg/ööpäevas.
Aripiprazole is effective in a dose range of 10 to 30 mg/day.
Aripirasool on efektiivne annuste vahemikus 10...30 mg/ööpäevas.
Aripiprazole is metabolised by multiple pathways involving the CYP2D6 and CYP3A4 enzymes, but not CYP1A enzymes.
Aripiprasooli metabolism kulgeb mööda mitut rada ensüümide CYP2D6 ja CYP3A4 kaudu, kuid mitte CYP1A vahendusel.
Aripiprazole is not indicated for the treatment of dementia-related psychosis.
Aripiprasool ei ole näidustatud dementsusega kaasneva psühhoosi raviks.
Aripiprazole is not indicated for the treatment of dementia-related psychosis.
Aripiprasool ei ole näidustatud dementsusele kaasneva psühhoosi raviks.
Aripiprazole is not recommended for use in patients with schizophrenia below 15 years of age due to insufficient data on safety and efficacy (see sections 4.8 and 5.1).
Ebapiisavate ohutuse ja efektiivsuse andmete tõttu ei ole aripirasool soovitatav kasutamiseks noorematele kui 15 aasta vanustele skisofreenia patsientidele (vt lõigud 4.8 ja 5.1).
Aripiprazole is the predominant medicinal product moiety in systemic circulation.
Peamise süsteemses vereringes olevast aktiivsusest moodustab aripiprasool.
Aripiprazole is the predominant medicinal product moiety in systemic circulation.
Peamise süsteemsest tsirkulatsioonis olevast aktiivsusest moodustab muutumatu aripiprasool.
Aripiprazole is thought to act mainly by being a ‘partial agonist’ at the receptors for the neurotransmitters dopamine and 5-hydroxytryptamine (also called serotonin).
Arvatakse, et aripiprasool mõjub põhiliselt neurotransmitterite dopamiini ja 5-hüdroksütrüptamiini (serotoniini) retseptorite osalise agonistina.
Aripiprazole is thought to act mainly by being a ‘partial agonist’ for the receptors for the neurotransmitters dopamine and 5- hydroxytryptamine (also called serotonin).
Arvatakse, et aripiprasool mõjub põhiliselt neurotransmitterite dopamiini ja 5-hüdroksütrüptamiini (serotoniini) retseptorite osalise agonistina.
Aripiprazole is thought to act mainly by being a ‘partial agonist’ for the receptors for the neurotransmitters dopamine and 5-hydroxytryptamine (also called serotonin).
Arvatakse, et aripiprasool mõjub põhiliselt neurotransmitterite dopamiini ja 5-hüdroksütrüptamiini (serotoniini) retseptorite osalise agonistina.
Aripiprazole Long-Acting Injectable
Aripiprasooli pikatoimeline süst
Aripiprazole Mylan
Aripiprazole
Aripiprazole Mylan Pharma
Aripiprazole
Aripiprazole Mylan Pharma 10 mg tablets
Aripiprazole Mylan Pharma 10 mg tabletid
Aripiprazole Mylan Pharma 10 mg tablets
Aripiprazole Mylan Pharma 10 mg tabletid EU/1/15/1005/004
Aripiprazole Mylan Pharma 10 mg tablets are pink, round and biconvex of 8.1mm in diameter, engraved with ‘10’ on one side.
Aripiprazole Mylan Pharma 10 mg tabletid on roosad ümmargused kaksikkumerad tabletid diameetriga 8,1 mm, ühele küljele on pressitud "10".
Aripiprazole Mylan Pharma 10 mg tablets aripiprazole
Aripiprazole Mylan Pharma 10 mg tabletid aripiprazole
Aripiprazole Mylan Pharma 10 mg tablets aripiprazole
Aripiprazole Pharmaten 10 mg tabletid aripiprazole
Aripiprazole Mylan Pharma 10 mg tablets Each tablet contains 10 mg of aripiprazole.
Aripiprazole Mylan Pharma 10 mg tabletid Ukstablett sisaldab 10 mg aripiprasooli.
Aripiprazole Mylan Pharma 15 mg tablets
Aripiprazole Mylan Pharma 15 mg tabletid
Aripiprazole Mylan Pharma 15 mg tablets
Aripiprazole Mylan Pharma 15 mg tabletid EU/1/15/1005/007
Aripiprazole Mylan Pharma 15 mg tablets are yellow, round and biconvex of 10.1mm in diameter, engraved with ‘15’ on one side.
Aripiprazole Mylan Pharma 15 mg tabletid on kollased ümmargused kaksikkumerad tabletid diameetriga 10,1 mm, ühele küljele on pressitud "15".
Aripiprazole Mylan Pharma 15 mg tablets aripiprazole
Aripiprazole Mylan Pharma 15 mg tabletid aripiprazole
Aripiprazole Mylan Pharma 15 mg tablets Each tablet contains 15 mg of aripiprazole.
Aripiprazole Mylan Pharma 15 mg tabletid Ukstablett sisaldab 15 mg aripiprasooli.
Aripiprazole Mylan Pharma 30 mg tablets
Aripiprazole Mylan Pharma 30 mg tabletid EU/1/15/1005/010
Aripiprazole Mylan Pharma 30 mg tablets are pink, oval and biconvex of 17.1mm in length, 8.1mm in width, engraved with ‘30’ on one side.
Aripiprazole Mylan Pharma 30 mg tabletid on roosad ovaalsed kaksikkumerad tabletid pikkusega 17,1 mm ja laiusega 8,1 mm, ühele küljele on pressitud "30".
Aripiprazole Mylan Pharma 30 mg tablets aripiprazole
Aripiprazole Mylan Pharma 30 mg tabletid aripiprazole
Aripiprazole Mylan Pharma 30 mg tablets Each tablet contains 30 mg of aripiprazole.
Aripiprazole Mylan Pharma 30 mg tabletid Ukstablett sisaldab 30 mg aripiprasooli.
Aripiprazole Mylan Pharma 5 mg tablets
Aripiprazole Mylan Pharma 5 mg tabletid
Aripiprazole Mylan Pharma 5 mg tablets aripiprazole
Aripiprazole Mylan Pharma 5 mg tabletid aripiprazole
Aripiprazole Mylan Pharma 5 mg tablets aripiprazole
AripiprazoleMylan Pharma 5 mg tabletid aripiprazole
Aripiprazole Mylan Pharma 5 mg tablets Aripiprazole Mylan Pharma 10 mg tablets Aripiprazole Mylan Pharma 15 mg tablets Aripiprazole Mylan Pharma 30 mg tablets
Aripiprazole Mylan Pharma 5 mg tabletid Aripiprazole Mylan Pharma 10 mg tabletid Aripiprazole Mylan Pharma 15 mg tabletid Aripiprazole Mylan Pharma 30 mg tabletid
Aripiprazole Mylan Pharma 5 mg tablets Each tablet contains 5 mg of aripiprazole.
Aripiprazole Mylan Pharma 5 mg tabletid Ukstablett sisaldab 5 mg aripiprasooli.
Aripiprazole Mylan Pharma contains the active substance aripiprazole and is a ‘generic medicine’.
Aripiprazole Mylan Pharma sisaldab toimeainena aripiprasooli ja on geneeriline ravim.
Aripiprazole Mylan Pharma is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older (see section 5.1).
Aripiprazole Mylan Pharma on näidustatud I tüüpi bipolaarse meeleoluhäire mõõduka kuni raske maniakaalse episoodi kuni 12 nädalaseks raviks noorukitel vanuses 13 aastat ja üle selle (vt lõik 5.1).
Aripiprazole Mylan Pharma tablets are used to treat adults and adolescents aged 13 years and older who suffer from a condition with symptoms such as feeling "high", having excessive amounts of energy, needing much less sleep than usual, talking very quickly with racing ideas and sometimes severe irritability.
Aripiprazole Mylan Pharma tablette kasutatakse nende täiskasvanute ning noorukite vanuses 13 aastat ja vanemad raviks, kellel haiguse korral esinevad sellised sümptomid, nagu kõrgenenud meeleolu, ülemäärane energilisusa, tavalisest väiksem unevajadus, kiire ideederikas kõne ning mõnikord ka suurenenud ärritatavus.
Aripiprazole Mylan Pharma tablets contain maltose
Aripiprazole Mylan Pharma tabletid sisaldavad maltoosi
Aripiprazole Mylan Pharma tablets contain the active substance aripiprazole and belong to a group of medicines called antipsychotics.
Aripiprazole Mylan Pharma tabletid sisaldavad toimeainet aripiprasooli ja kuuluvad antipsühhootiliste ravimite rühma.
Aripiprazole Mylan Pharma1 aripiprazole
Aripiprazole Mylan Pharma1 aripiprasool
Aripiprazole Sandoz 10 mg tablets are pink coloured, mottled, round shaped tablets, with an approximate diameter of 6.0 mm, debossed with “SZ” on one side and “446” on the other side.
Aripiprazole Sandoz 10 mg tabletid on roosad kirjud ümarad, ligikaudu 6,0 mm läbimõõduga tabletid, mille ühel küljel on graveering "SZ" ja teisel "446".
Aripiprazole Sandoz 10 mg tablets aripiprazole
Aripiprazole Sandoz 10 mg tabletid aripiprasool
Aripiprazole Sandoz 15 mg tablets are yellow coloured, mottled, round shaped tablets, with an approximate diameter of 7.0 mm, debossed with “SZ” on one side and “447” on the other side.
Aripiprazole Sandoz 15 mg tabletid on kollased kirjud ümarad, ligikaudu 6,0 mm läbimõõduga tabletid, mille ühel küljel on graveering "SZ" ja teisel "447".
Aripiprazole Sandoz 15 mg tablets aripiprazole
Aripiprazole Sandoz 15 mg tabletid aripiprasool
Aripiprazole Sandoz 20 mg tablets are white coloured, round shaped tablets, with an approximate diameter of 7.8 mm, debossed with “SZ” on one side and “448” on the other side.
Aripiprazole Sandoz 20 mg tabletid on valged ümarad, ligikaudu 7,8 mm läbimõõduga tabletid, mille ühel küljel on graveering "SZ" ja teisel "448".
Aripiprazole Sandoz 20 mg tablets aripiprazole
Aripiprazole Sandoz 20 mg tabletid aripiprasool
Aripiprazole Sandoz 30 mg tablets are pink coloured, mottled, round shaped tablets, with an approximate diameter of 9.0 mm, debossed with “SZ” on one side and “449” on the other side.
Aripiprazole Sandoz 30 mg tabletid on roosad kirjud ümarad, ligikaudu 9,0 mm läbimõõduga tabletid, mille ühel küljel on graveering "SZ" ja teisel "449".
Aripiprazole Sandoz 30 mg tablets aripiprazole
Aripiprazole Sandoz 30 mg tabletid aripiprasool
Aripiprazole Sandoz 5 mg tablets aripiprazole
Aripiprazole Sandoz 5 mg tabletid aripiprasool
Aripiprazole Sandoz 5 mg tabletsLactose monohydrate Maize starch
Aripiprazole Sandoz 5 mg tabletid
Aripiprazole Sandoz 5 mg, 10 mg, 15 mg, 30 mg tablets
Aripiprazole Sandoz 5 mg, 10 mg, 15 mg, 30 mg tabletid
Aripiprazole Sandoz contains the active substance aripiprazole and is a ‘generic’ and a ‘hybrid’ medicine.
Aripiprazole Sandoz sisaldab toimeainena aripiprasooli ning on geneeriline ja hübriidravim.
Aripiprazole Sandoz is effective in a dose range of 10 to 30 mg/day.
Aripiprazole Sandoz on efektiivne annuste vahemikus 10...30 mg/ööpäevas.
Aripiprazole Sandoz is not recommended for use in patients with schizophrenia below 15 years of age due to insufficient data on safety and efficacy (see sections 4.8 and 5.1).
Aripiprazole Sandoz’t ei soovitata kasutada alla 15 aasta vanuste skisofreeniaga patsientidel ohutuse ja efektiivsuse ebapiisavate andmete tõttu (vt lõigud 4.8 ja 5.1).
Aripiprazole Sandoz is used in patients aged 15 years or over; bipolar I disorder, a mental illness in which patients have manic episodes (periods of abnormally high mood), alternating with periods of normal mood.
I tüüpi bipolaarne meeleoluhäire – vaimuhaigus, mille korral patsientide maaniaepisoodid (meeleolu äärmuslik tõus) vahelduvad normaalse meeleolu perioodidega.